These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17587262)

  • 1. Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: analysis from the 17th nationwide survey.
    Uehara R; Yashiro M; Oki I; Nakamura Y; Yanagawa H
    Pediatr Int; 2007 Aug; 49(4):427-30. PubMed ID: 17587262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM; Shulman ST
    J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
    Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulin failure and retreatment in Kawasaki disease.
    Durongpisitkul K; Soongswang J; Laohaprasitiporn D; Nana A; Prachuabmoh C; Kangkagate C
    Pediatr Cardiol; 2003; 24(2):145-8. PubMed ID: 12457253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
    Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
    Kobayashi T; Kobayashi T; Morikawa A; Ikeda K; Seki M; Shimoyama S; Ishii Y; Suzuki T; Nakajima K; Sakamoto N; Arakawa H
    J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of early intravenous immunoglobulin therapy for Kawasaki disease: The 22nd nationwide survey in Japan.
    Kuwabara M; Yashiro M; Ae R; Yanagawa H; Nakamura Y
    Int J Cardiol; 2018 Oct; 269():334-338. PubMed ID: 30049499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of responsiveness or non-responsiveness to treatment of acute Kawasaki disease using 1 gram per kilogram of immunoglobulin--an effective and cost-saving schedule of therapy.
    Ichihashi K; Shiraishi H; Momoi M
    Cardiol Young; 2009 Jun; 19(3):224-7. PubMed ID: 19272202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
    Wooditch AC; Aronoff SC
    Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial.
    Kuo HC; Guo MM; Lo MH; Hsieh KS; Huang YH
    BMC Pediatr; 2018 Jun; 18(1):200. PubMed ID: 29933749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the treatment of Kawasaki disease.
    Dominguez SR; Anderson MS
    Curr Opin Pediatr; 2013 Feb; 25(1):103-9. PubMed ID: 23283289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marker of T-cell activation is elevated in refractory Kawasaki disease.
    Suzuki H; Suenaga T; Takeuchi T; Shibuta S; Yoshikawa N
    Pediatr Int; 2010 Oct; 52(5):785-9. PubMed ID: 20487370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group.
    Burns JC; Capparelli EV; Brown JA; Newburger JW; Glode MP
    Pediatr Infect Dis J; 1998 Dec; 17(12):1144-8. PubMed ID: 9877364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study.
    Kanai T; Ishiwata T; Kobayashi T; Sato H; Takizawa M; Kawamura Y; Tsujimoto H; Nakatani K; Ishibashi N; Nishiyama M; Hatai Y; Asano Y; Kobayashi T; Takeshita S; Nonoyama S
    Circulation; 2011 Dec; 124(25):2822-8. PubMed ID: 22104548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of acute and refractory Kawasaki disease.
    Tacke CE; Burgner D; Kuipers IM; Kuijpers TW
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1203-15. PubMed ID: 23199405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.